Esperion Therapeutics (NASDAQ:ESPR) Vs. MCRB, ANAB, PAHC, OLMA, ARQT, KNTE, CELU, GOSS, SNDX, and KNSA
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Seres Therapeutics (MCRB), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Olema Pharmaceuticals (OLMA), Arcutis Biotherapeutics (ARQT), Kinnate Biopharma (KNTE), Celularity (CELU), Gossamer Bio (GOSS), Syndax Pharmaceuticals (SNDX), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.
Esperion Therapeutics vs.
Esperion Therapeutics (NASDAQ:ESPR) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.
In the previous week, Esperion Therapeutics had 5 more articles in the media than AnaptysBio. MarketBeat recorded 5 mentions for Esperion Therapeutics and 0 mentions for AnaptysBio. Esperion Therapeutics' average media sentiment score of 0.25 beat AnaptysBio's score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media.
Esperion Therapeutics received 240 more outperform votes than AnaptysBio when rated by MarketBeat users. Likewise, 71.38% of users gave Esperion Therapeutics an outperform vote while only 70.59% of users gave AnaptysBio an outperform vote.
AnaptysBio has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
Esperion Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.
AnaptysBio has a net margin of 6.87% compared to Esperion Therapeutics' net margin of -424.39%. AnaptysBio's return on equity of 2.17% beat Esperion Therapeutics' return on equity.
Esperion Therapeutics presently has a consensus price target of $40.36, suggesting a potential upside of 418.81%. AnaptysBio has a consensus price target of $35.50, suggesting a potential upside of 14.07%. Given Esperion Therapeutics' higher possible upside, equities analysts plainly believe Esperion Therapeutics is more favorable than AnaptysBio.
98.8% of Esperion Therapeutics shares are held by institutional investors. 7.3% of Esperion Therapeutics shares are held by insiders. Comparatively, 34.9% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
AnaptysBio beats Esperion Therapeutics on 10 of the 19 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics (NASDAQ:ESPR) vs. Its Competitors
Esperion Therapeutics Competitors List
